ERBB2 and breast carcinoma: Troponin-I and Brain Natriuretic Peptide (BNP), the marker of myocardial cell injury, tends to be elevated in patients receiving anti-HER2 therapy following prior chemotherapy for breast cancer, indicating a higher risk of cardiac dysfunction [24].